Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer

Bookmark and Share
Published: 24 Oct 2018
Views: 849
Rating:
Save
Dr Maria Vittoria Dieci - University of Padua, Padova, Italy

Dr Maria Vittoria Dieci speaks with ecancer at ESMO 2018 in Munich about results from a sub study from the larger shortHER trial where they looked at tumour-infiltrating lymphocytes as an independent prognostic factor for early HER2 positive breast cancer patients.

Dr Dieci found a significant association between increased tumour-infiltrating lymphocytes and improved metastasis free survival.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.